← Back to headlines
Eli Lilly sees strong growth from Mounjaro and GLP-1 demand
Eli Lilly (LLY) is experiencing robust growth, primarily driven by the momentum of its drug Mounjaro and increasing demand for GLP-1 medications, leading Barclays to maintain a bullish outlook on the company.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Netflix to Close Gaming Studios, Including One in Finland
3h ago
Reliance and Rolls-Royce Partner for Indian Fighter Jet Engine Development
3h ago
FDA Issues Class I Recall for 1.6 Million Cartons of Eggs Due to Salmonella Risk
4h ago
Berkshire Hathaway Increases Stakes in Alphabet, Delta, and Housing
5h ago